Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micromet Inc (MITI) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (9)	2/8/2006 2:18:34 PM
From: dr.praveen	Respond to of 196

Hi Wilder, Very optimistic based on the following preclinical data: The results published in the British Journal of Cancer1 demonstrate that MT201 effectively mediates the elimination of various human breast cancer cell lines. A panel of the nine most commonly used breast cancer cell lines was investigated and the anti-tumor activity of MT201 compared to that of Herceptin®, a humanized antibody against the HER-2 antigen. When averaged over the nine cell lines, both antibodies showed a comparable effect in engaging human immune effector cells for tumor cell elimination, an activity referred to as antibody-dependent cellular cytotoxicity (ADCC). In view of a more frequent overexpression of Ep-CAM than HER-22 and a functional role of Ep-CAM in breast cancer,3,4 the new findings indicate that MT201 may considerably expand the segment of breast cancer patients qualifying for antibody-based therapy. This will be my last post for the day since I have a limited acc. You can post your views and I will reply late tonight. Regards, Praveen